Appili Financial Statements From 2010 to 2025

APLI Stock  CAD 0.04  0.00  0.00%   
Appili Therapeutics financial statements provide useful quarterly and yearly information to potential Appili Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Appili Therapeutics financial statements helps investors assess Appili Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Appili Therapeutics' valuation are summarized below:
Gross Profit
1.4 M
Market Capitalization
4.2 M
Enterprise Value Revenue
28.2974
Revenue
827.4 K
Earnings Share
(0.03)
We have found one hundred twenty available fundamental signals for Appili Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Appili Therapeutics' prevailing fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 8th of January 2025, Enterprise Value is likely to grow to about 22.5 M, while Market Cap is likely to drop about 4.6 M.

Appili Therapeutics Total Revenue

999,094

Check Appili Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Appili Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 18.4 K, Depreciation And Amortization of 11.4 K or Interest Expense of 2 M, as well as many indicators such as Price To Sales Ratio of 5.6, Dividend Yield of 0.0 or Days Sales Outstanding of 527. Appili financial statements analysis is a perfect complement when working with Appili Therapeutics Valuation or Volatility modules.
  
This module can also supplement various Appili Therapeutics Technical models . Check out the analysis of Appili Therapeutics Correlation against competitors.

Appili Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.3 M1.3 M4.8 M
Pretty Stable
Short and Long Term Debt Total9.9 M9.4 MM
Slightly volatile
Other Current Liabilities64.8 K68.2 K459.8 K
Slightly volatile
Total Current Liabilities13.9 M13.3 M3.9 M
Slightly volatile
Property Plant And Equipment Net42.7 K27.1 K50.9 K
Slightly volatile
Accounts Payable3.1 M4.7 M2.2 M
Slightly volatile
Cash80.8 K85 K3.2 M
Pretty Stable
Non Current Assets Total42.7 K27.1 K50.9 K
Slightly volatile
Other Assets0.80.90.9813
Slightly volatile
Long Term Debt956.2 KM1.4 M
Slightly volatile
Cash And Short Term Investments80.8 K85 K3.5 M
Pretty Stable
Net Receivables817.8 K1.1 MM
Pretty Stable
Common Stock Shares Outstanding146.4 M139.5 M59.8 M
Slightly volatile
Long Term Debt Total9.1 M8.7 M2.8 M
Slightly volatile
Liabilities And Stockholders Equity1.3 M1.3 M4.8 M
Pretty Stable
Non Current Liabilities Total956.2 KM1.4 M
Slightly volatile
Capital Surpluse7.7 M7.4 M2.5 M
Slightly volatile
Other Current Assets231.3 K221.3 K163.2 K
Slightly volatile
Total Liabilities15 M14.3 M5.3 M
Slightly volatile
Total Current Assets1.2 M1.3 M4.8 M
Pretty Stable
Common Stock28.4 M48.7 M19.2 M
Slightly volatile
Property Plant Equipment12.5 K13.1 K47.2 K
Slightly volatile
Common Stock Total Equity15.8 M24.1 M15.3 M
Slightly volatile
Short and Long Term Debt8.8 M8.4 M1.6 M
Slightly volatile
Capital Stock35.1 M48.7 M22.7 M
Slightly volatile
Property Plant And Equipment Gross85.1 K74.6 K116.8 K
Slightly volatile

Appili Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization11.4 K12.3 K12.5 K
Pretty Stable
Selling General Administrative3.5 M3.5 M2.5 M
Slightly volatile
Selling And Marketing Expenses122.8 K129.3 K282.5 K
Slightly volatile
Other Operating Expenses10.8 M10.2 M7.6 M
Slightly volatile
Research Development7.8 M6.5 M5.4 M
Slightly volatile
Cost Of Revenue11.2 K12.3 K12 K
Very volatile
Total Operating Expenses10.8 M10.2 M7.6 M
Slightly volatile
Reconciled Depreciation11.8 K12.3 K15.7 K
Slightly volatile

Appili Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock8.4 M5.2 M5.3 M
Slightly volatile
Stock Based Compensation209 K220 K464.9 K
Slightly volatile
Depreciation11.4 K12.3 K12.5 K
Pretty Stable
Capital Expenditures14.8 K26.7 K25.8 K
Slightly volatile
Total Cash From Financing Activities212.6 K223.8 K4.4 M
Pretty Stable
End Period Cash Flow80.8 K85 K3.2 M
Pretty Stable
Change To Netincome4.3 M4.1 M1.4 M
Slightly volatile
Begin Period Cash Flow2.7 M2.8 M3.6 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio5.65.975.8796
Slightly volatile
Days Sales Outstanding527595536
Slightly volatile
Average Payables2.8 MM2.7 M
Slightly volatile
Stock Based Compensation To Revenue0.250.271.8276
Slightly volatile
Capex To Depreciation1.652.52.2743
Slightly volatile
EV To Sales32.4817.1449.8588
Slightly volatile
Inventory Turnover0.140.180.179
Slightly volatile
Days Of Inventory On Hand2.2 K2.1 KK
Slightly volatile
Payables Turnover0.00280.00290.0093
Slightly volatile
Sales General And Administrative To Revenue4.024.2412.2516
Slightly volatile
Research And Ddevelopement To Revenue13.427.8113.8745
Slightly volatile
Capex To Revenue0.03390.03230.0116
Slightly volatile
Cash Per Share9.0E-49.0E-40.0856
Very volatile
Days Payables Outstanding136.6 K130.1 K72 K
Slightly volatile
Income Quality0.960.750.9973
Slightly volatile
Current Ratio0.140.153.0339
Slightly volatile
Receivables Turnover0.620.630.6939
Slightly volatile
Graham Number0.270.290.4282
Slightly volatile
Capex Per Share3.0E-43.0E-47.0E-4
Slightly volatile
Average Receivables1.3 M916.6 K1.4 M
Slightly volatile
Revenue Per Share0.010.00780.008
Slightly volatile
Operating Cycle1.1 K5951.4 K
Slightly volatile
Days Of Payables Outstanding136.6 K130.1 K72 K
Slightly volatile
Ebt Per Ebit0.680.410.7214
Pretty Stable
Quick Ratio0.140.153.022
Slightly volatile
Net Income Per E B T0.750.920.8568
Slightly volatile
Cash Ratio0.00890.00942.0514
Pretty Stable
Days Of Inventory Outstanding2.2 K2.1 KK
Slightly volatile
Days Of Sales Outstanding527595536
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.161.0266
Slightly volatile
Fixed Asset Turnover17.2824.7111.8499
Slightly volatile
Price Sales Ratio5.65.975.8796
Slightly volatile
Asset Turnover0.520.50.1372
Slightly volatile
Gross Profit Margin0.780.880.9623
Slightly volatile

Appili Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4.6 M4.9 M21 M
Slightly volatile
Enterprise Value22.5 M14.2 M21.2 M
Pretty Stable

Appili Fundamental Market Drivers

Forward Price Earnings2.3776
Cash And Short Term Investments94.5 K

About Appili Therapeutics Financial Statements

Appili Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Appili Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue54.2 K56.9 K
Total Revenue951.5 K999.1 K
Cost Of Revenue12.3 K11.2 K
Stock Based Compensation To Revenue 0.27  0.25 
Sales General And Administrative To Revenue 4.24  4.02 
Research And Ddevelopement To Revenue 7.81  13.42 
Capex To Revenue 0.03  0.03 
Revenue Per Share 0.01  0.01 
Ebit Per Revenue(8.76)(9.19)

Pair Trading with Appili Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Appili Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Appili Therapeutics will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Appili Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Appili Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Appili Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Appili Therapeutics to buy it.
The correlation of Appili Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Appili Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Appili Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Appili Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Appili Stock

Appili Therapeutics financial ratios help investors to determine whether Appili Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Appili with respect to the benefits of owning Appili Therapeutics security.